2.4774
Annexon Inc stock is traded at $2.4774, with a volume of 494.47K.
It is up +3.13% in the last 24 hours and up +21.32% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$2.40
Open:
$2.37
24h Volume:
494.47K
Relative Volume:
0.28
Market Cap:
$289.65M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-1.3997
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
+1.02%
1M Performance:
+21.32%
6M Performance:
-51.75%
1Y Performance:
-50.99%
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ANNX
Annexon Inc
|
2.48 | 289.65M | 0 | -134.24M | -121.34M | -1.77 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.17 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
538.05 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
323.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
550.53 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.06 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
Oct-30-23 | Initiated | Wells Fargo | Overweight |
May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
Sep-16-22 | Initiated | Jefferies | Buy |
Sep-09-22 | Initiated | BTIG Research | Buy |
Nov-30-21 | Initiated | H.C. Wainwright | Buy |
Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Jan-26-21 | Initiated | Needham | Buy |
Aug-18-20 | Initiated | BofA Securities | Buy |
Aug-18-20 | Initiated | Cowen | Outperform |
Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon says enrollment of Phase 3 Archer II Trial expected to be completed in Q3 2025 - MarketScreener
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrop - GuruFocus
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) - GlobeNewswire
Bank of America Corp DE Sells 137,220 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Sold by Park Avenue Securities LLC - Defense World
Market Highlights: Annexon Inc (ANNX) Ends on a Low Note at 2.49 - DWinneX
Annexon Inc (ANNX) Stock: A Comprehensive 52-Week Review - investchronicle.com
49,062 Shares in Annexon, Inc. (NASDAQ:ANNX) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Bought by California State Teachers Retirement System - Defense World
Cantor Fitzgerald Estimates Annexon FY2026 Earnings - Defense World
Annexon Biosciences Holds Annual Stockholders Meeting - TipRanks
Two Sigma Advisers LP Reduces Stock Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Squarepoint Ops LLC Sells 49,438 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Millennium Management LLC Grows Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Transcript : Annexon, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com
Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.
BNP Paribas Financial Markets Makes New $59,000 Investment in Annexon, Inc. (NASDAQ:ANNX) - Defense World
ProShare Advisors LLC Buys 14,475 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Bought by Jane Street Group LLC - Defense World
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference | ANNX Stock News - GuruFocus
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Nuveen Asset Management LLC Acquires 164,915 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Janus Henderson Group PLC Invests $177,000 in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Stock Holdings Raised by Ameriprise Financial Inc. - Defense World
Deutsche Bank AG Acquires 28,448 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Northern Trust Corp - Defense World
Annexon reports promising Guillain-Barré treatment results By Investing.com - Investing.com India
Annexon (ANNX) Highlights Promising Results from Tanruprubart Ph - GuruFocus
Annexon reports promising Guillain-Barré treatment results - Investing.com Australia
Annexon Showcases Tanruprubart Data Demonstrating Improved Clini - GuruFocus
Annexon Showcases Tanruprubart Data Demonstrating Improved - GlobeNewswire
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting - The Manila Times
New GBS Drug Shows 3X Better Outcomes Than Standard Care in Clinical Trial | ANNX Stock News - Stock Titan
Annexon Inc (NASDAQ: ANNX) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | ANNX Stock News - GuruFocus
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Annexon Awards $387K Worth of Stock Options to New Hires: Inside the Compensation Package - Stock Titan
HC Wainwright Issues Negative Estimate for Annexon Earnings - Defense World
HC Wainwright Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
Needham & Company LLC Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Annexon (ANNX) Receives Revised Price Target from HC Wainwright - GuruFocus
Schonfeld Strategic Advisors LLC Sells 589,091 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Cantor Fitzgerald maintains Overweight on Annexon stock By Investing.com - Investing.com Nigeria
Annexon (ANNX) Sees Price Target Cut to $14 by H.C. Wainwright | - GuruFocus
Annexon Inc Reports Q1 2025 EPS of -$0.37, Missing Estimates; Re - GuruFocus
Annexon (ANNX) Maintains "Buy" Rating Despite Price Target Cut | ANNX Stock News - GuruFocus
Annexon Biosciences Reports Increased Q1 2025 Losses - TipRanks
Annexon, Inc. SEC 10-Q Report - TradingView
Annexon Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Annexon Inc Stock (ANNX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER |
Feb 18 '25 |
Sale |
2.97 |
5,515 |
16,380 |
83,814 |
Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 18 '25 |
Sale |
2.91 |
8,345 |
24,284 |
61,237 |
Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 18 '25 |
Sale |
2.95 |
6,618 |
19,523 |
86,579 |
Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 18 '25 |
Sale |
2.92 |
6,912 |
20,183 |
77,770 |
Love Douglas | PRESIDENT AND CEO |
Feb 13 '25 |
Sale |
2.95 |
5,021 |
14,812 |
351,554 |
Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 13 '25 |
Sale |
2.98 |
1,786 |
5,322 |
84,682 |
Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,425 |
4,261 |
93,197 |
Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,783 |
5,331 |
69,582 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):